Climb Bio, Inc. CLYM

Preliminary Phase 2 data from the ongoing PrisMN study of budoprutug in primary membranous nephropathy selected for oral presentation Presentations on CLYM116 and budoprutug programs highlight advancements across the portfolio WELLESLEY HILLS, Mass., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today announced that it will present new clinical data for its CLYM116 and b

Investing.com -- Raymond James has updated its Healthcare Top Picks list for October, adding three new stocks while removing others from the monthly selection. The firm added Xencor, Calyxt, and UnitedHealth Group to replace Relay Therapeutics, Tyra Biosciences, and Oscar Health.

Biotech stocks widely slumped Wednesday, with Rapport Therapeutics, Climb Bio and Cullinan Therapeutics among some of the hardest-hit names.

Zanvastro is now the first approved medicine for Alexander disease. Elsewhere, an immune system specialist posted positive results and a cell therapy developer turned to layoffs.

Climb Bio reversed course downward Thursday despite potential "best-in-class" data for its experimental kidney disease treatment.

Climb Bio, Inc. (NASDAQ:CLYM) shares rose 17% on Thursday after the clinical-stage biotechnology company released Phase 1 trial data for CLYM116, its anti-APRIL monoclonal antibody being developed for IgA nephropathy.

WELLESLEY HILLS, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today announced that members of its executive team will participate in the upcoming conferences detailed below. Wells Fargo 21st Annual Healthcare ConferenceFormat: Fireside ChatDate: Wednesday, September 9 Time: 4:30 – 5:05 p.m. ET Morgan Stanley 24th Annual Global Healthcare ConferenceFormat: Firesi

Climb Bio (CLYM) is back in focus after Beijing Mabworks Biotech began dosing the first patient with immunoglobulin A nephropathy in a Phase 2 clinical trial in China, highlighting their joint development efforts. The clinical update arrives while Climb Bio’s share price has moved sharply, with a 1-month share price return of 38.94% and a 90-day share price return of 49.16%. This has contributed to a year-to-date share price return of 375.73% and a very large 1-year total shareholder return,...

Climb Bio, Inc. reported its second-quarter 2026 earnings, posting a net loss of US$13.5 million versus US$8.67 million a year earlier, while basic loss per share from continuing operations widened to US$0.18 from US$0.13. Over the first six months of 2026, however, Climb Bio’s net loss narrowed to US$27.22 million from US$29.45 million, with basic loss per share improving to US$0.38 from US$0.44, highlighting mixed progress on its financial profile. With these mixed earnings trends,...

CLYM116 Phase 1 data in healthy volunteers to be presented at R&D Spotlight Event on September 3, 2026 Anticipate CLYM116 Phase 2 trial in IgA nephropathy to initiate dosing in Q3 2026 Budoprutug clinical programs continue to advance, with data expected from pMN, ITP, and SLE studies in Q4 2026 Financing extends cash runway into the second half of 2028 WELLESLEY HILLS, Mass., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical stage biotechnology company developing thera

Data demonstrate favorable safety and tolerability profile, robust B-cell depletion, and encouraging platelet responses in heavily pretreated patients with primary immune thrombocytopenia Enrollment ongoing in the high dose cohort, with additional data anticipated by year-end 2026 WELLESLEY HILLS, Mass., June 11, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today announced initi

Company to share additional CLYM116 clinical data and plans for further development at R&D Spotlight in late summer Initiation of CLYM116 dosing in IgAN patients in Mabworks Phase 2 study expected in Q3 2026 WELLESLEY HILLS, Mass., June 05, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today announced translational pharmacometric modeling and initial Phase 1 safety data for CLYM1

WELLESLEY HILLS, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today announced upcoming presentations for its CLYM116 and budoprutug programs at the European Renal Association Congress 2026, which will be held in Glasgow, Scotland June 3-6, 2026. Climb Bio will present pharmacokinetic/pharmacodynamic modeling from nonhuman primates to humans for CLYM116, a novel ‘s